Health Condition 1: L433- Subacute (active) lichen planus
Conditions
Interventions
Intervention1: Group A- oral prednisolone: 0.5mg/kg of oral prednisolone will be given to patients randomised into group A for a period of 8weeks and will be tapered gradually in subsequent follow up
Sponsors
Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER Pondicherry
Eligibility
Inclusion criteria
Inclusion criteria: patients with symptomatic active oral or mucocutaneous lichenplanus with BSA greater than 5 % who needs systenic therapy Symptomatic lesions of reticular, atrophic and erosive OLP, based on the clinical and histopathological criteria of the WHO (1978) and modified by van der Meij and van der Waal. Patients of oral LP with treatment failure after 4 weeks of topical therapy.
Exclusion criteria
Exclusion criteria: Patients with treatment naive mild lichen planus Patient with renal impairment Pregnancy,lactation and with serious medical illness Contraindications for Prednisolone/cyclosporine 8 weeks Defnitive drug induced lichenoid eruption Nail and hair,lichen planus, lichen planus pigmentosus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of oral cyclosporine in comparison with oral prednisolone (using severity score and VAS) in the management of lichen planusTimepoint: At baseline,8wks,12wks, and 24wks | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the side effect profile & to assess the duration of disease remission & the cost-effectiveness analysis between oral cyclopsporine group & oral prednisolone group in management of lichen planusTimepoint: At baseline ,8weeks,12 weeks & 24 weeks | — |
Countries
India
Contacts
Public ContactDr. Rashmi Kumari
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry
Outcome results
None listed